Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Corvus Pharmaceuticals (CRVS) EBIAT (2016 - 2026)

Corvus Pharmaceuticals' EBIAT history spans 12 years, with the latest figure at -$13.7 million for Q1 2026.

  • Quarterly EBIAT fell 190.12% to -$13.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$44.2 million through Mar 2026, down 6.69% year-over-year, with the annual reading at -$15.3 million for FY2025, 75.47% up from the prior year.
  • EBIAT came in at -$13.7 million for Q1 2026, down from -$12.3 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $15.2 million in Q1 2025 to a low of -$40.2 million in Q3 2024.
  • The 5-year median for EBIAT is -$8.3 million (2022), against an average of -$9.4 million.
  • Year-over-year, EBIAT tumbled 570.28% in 2024 and then surged 366.5% in 2025.
  • Corvus Pharmaceuticals' EBIAT stood at -$9.8 million in 2022, then skyrocketed by 32.17% to -$6.7 million in 2023, then plummeted by 82.07% to -$12.1 million in 2024, then fell by 1.72% to -$12.3 million in 2025, then dropped by 11.13% to -$13.7 million in 2026.
  • Per Business Quant, the three most recent readings for CRVS's EBIAT are -$13.7 million (Q1 2026), -$12.3 million (Q4 2025), and -$10.2 million (Q3 2025).